InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$18.66

2026-10-16

Market Cap

$21.4B

Volume

9.4M

52-Wk High

$18.66

52-Wk Low

$9.92

Trailing PE

-51.8

P/S

1.45

Gross Margin

34.8%

Net Margin

-2.8%

ROE

-3%

ROIC

-0%

Piotroski

7/9

Altman Z

1.1

1-Yr Return

+87.0%

5-Yr Return

+19.7%

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericExchangeNASDAQMarket Cap$21.4BEmployees30,000 (SEC-filed)CEOScott Andrew SmithIPO1980-03-17CountryUS

Robert J. Coury Global Center, Canonsburg, PA 15317 · Tel 724 514 1800 · viatris.com

INSIDERSTREET SCORE37 / 100Street mean $22.75 (4 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$1M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · VTRS +87.0% · S&P 500 +15.9% · spread +71.1pp

7 Years vs S&P 500 · VTRS +19.7% · S&P 500 +189.9% · spread -170.2pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE37of 100

Score Breakdown

Profitability	12/100
Growth	71/100
Momentum	68/100
Quality	48/100
Earnings Quality	43/100
Balance Sheet	36/100
Value	49/100
Risk (safety)	15/100
Overall	37.1/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
ZTS	66
ELAN	26
TEVA	40
ALKS	41
LNTH	66
AMRX	49
VTRS	37

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 46 in 23 Q1, latest 37 — -9 since. Dropped below the 40 line in 23 Q4, at 29. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY37 / 100IS Score 37.1 / 100 · -9.2 from peak of 46

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 92 / 100 · Power +83 · 22 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 37, price structure 92 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 37.1	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 19 → 20 → 34 → 37	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,030 → now 1,028	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)0 buysnone disclosed

Insider Buys (180d)0none disclosed

ETF Funds (30d)643 up / 603 downnet +40 funds

Institutions Added (13F)8managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,030 · latest 1,028 (-2 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,028	1059.2M	$15.5B	91.0%
2026 Q1	1,020	990.8M	$12.4B	85.2%
2025 Q4	1,003	977.4M	$11.3B	84.0%
2025 Q3	965	960.4M	$8.7B	82.6%
2025 Q2	975	975.7M	$8.0B	83.9%
2025 Q1	1,005	973.5M	$7.8B	83.7%
2024 Q4	1,030	998.0M	$11.9B	85.8%
2024 Q3	994	954.4M	$10.5B	82.0%
2024 Q2	995	978.0M	$9.7B	84.1%
2024 Q1	1,005	964.2M	$11.2B	82.9%
2023 Q4	1,007	958.6M	$9.9B	82.4%
2023 Q3	949	939.5M	$8.7B	80.8%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Simmons David S	director	2026-09-30	A-Award	2,117	—	4,479
Groothuis Leo Frans	director	2026-09-30	A-Award	2,469	—	5,225
Enrietti Andrew	See Remarks	2026-08-15	EXERCISE	25,134	—	244,811
Enrietti Andrew	See Remarks	2026-08-15	TAX W/H	10,931	$0.18M	233,880
Enrietti Andrew	See Remarks	2026-08-15	EXERCISE	999	—	234,879
Enrietti Andrew	See Remarks	2026-08-15	TAX W/H	435	$0.01M	234,444
Enrietti Andrew	See Remarks	2026-08-15	EXERCISE	25,134	—	50,267
Enrietti Andrew	See Remarks	2026-08-15	EXERCISE	998	—	1,997

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	2	71,426	$1.1M	Counted
M — Exercises (paired A/D)	51	2,553,127	—	None — mechanics
F — Tax withholding	35	944,631	$14.0M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$1.1M2 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-06-25	Paul Campbell	50,076	$0.8M
2026-03-23	Paul Campbell	21,350	$0.3M
2025-09-11	Le Goff Corinne	7,032	$0.1M
2024-11-12	Campbell Paul	26,925	$0.3M
Trailing 12 mo	3 filings	78,458	$1M

Filed	Form	Reporting person	% of class	Shares
2026-09-08	SCHEDULE 13G/A	Abigail P. Johnson	11.00%	126.8M sh
2026-08-12	SCHEDULE 13G/A	DAVIS SELECTED ADVISERS	6.50%	75.2M sh
2026-08-06	SCHEDULE 13G	Abigail P. Johnson	8.30%	96.4M sh
2026-05-05	SCHEDULE 13G/A	DAVIS SELECTED ADVISERS	6.80%	78.2M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Gilbert Cisneros	House	BUY	$1,001 - $15,000	2025-11-18	2025-12-15
Gilbert Ray Cisneros	House	BUY	$1,001 - $15,000	2025-11-17	2025-12-15
Rob Bresnahan	House	SELL	$1,001 - $15,000	2025-04-08	2025-05-08
John Fetterman	Senate	SELL	$1,001 - $15,000	2025-04-22	2025-05-15
John Karl Fetterman	Senate	SELL	$1,001 - $15,000	2025-04-22	2025-05-15
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2022-08-01	2022-09-15

House 12-Mo2 trades2 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,020

13F Shares991M85.2% of shares out

New / Closed137 / 96positions, QoQ

Increased / Reduced348 / 316positions, QoQ

Put/Call (13F)0.76option positions

Free Float99.4%1.14B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	10.5M	$187M
Argent Capital Management Llc	3.8M	$66M
Wedge Capital Management L L P/Nc	1.5M	$26M
Thompson Investment Management, In	1.0M	$19M
Continental Advisors Llc	714,750	$13M
Sound Income Strategies, Llc	659,514	$12M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.0%	$646M
VTSAX	0.0%	$646M
VSMPX	0.0%	$646M
VTI	0.0%	$646M
VFIAX	0.0%	$534M
VFFSX	0.0%	$534M

13F Filers Holding VTRS — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session53.9%2026-10-15

20-Day Avg44.0%50-day 50.8%

TrendFalling20d vs 50d

By Market CenterQ: 54% · N: 54% · B: 58%latest session

Weekly Notional ($B)

Where VTRS Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	6.8M	107 sh
Ubsa Ubs Ats	5.3M	130 sh
Mstx Ms Trajectory Cross (Ats-1)	5.0M	150 sh
Ebxl Level Ats	4.1M	50 sh
Bids Bids Ats	3.3M	1,005 sh
Jpbx Jpb-X	2.8M	172 sh

Where a dollar of Viatris Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
Developed Markets	$8.6B	60%
Greater China	$2.3B	16%
Emerging Markets	$2.2B	16%
Japan, Australia and New Zealand	$1.2B	8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

VTRS (live moat model)Peer median: ZTS · ELAN · TEVA · ALKS · LNTH

Component scores from the live moat model. Peer median illustrative.

Moat score 36/100 — None; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Scott Andrew Smith	Chief Executive Officer & Director
Paul Campbell	Interim CFO, Chief Accounting Officer & Corporate Controller
Corinne Le Goff	Chief Commercial Officer
Matthew Joseph Maletta	Chief Legal Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+10.1%

Next Report2026-11-05

Income QualityN/Mloss-making — OCF ÷ net income not meaningful

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+49.7%	-9.1%	-5.1%	-4.5%	-3.0%
Gross profit	+46.9%	+16.5%	-0.9%	-12.7%	-10.8%
Operating income	-83.9%	-4849.7%	-52.6%	-98.7%	-26467.3%
Net income	+89.4%	-263.8%	-97.4%	-1259.4%	+454.2%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	17.9	16.3	15.4	14.7	14.3
Cost of revenue	12.3	9.8	9.0	9.1	9.3
Gross profit	5.6	6.5	6.4	5.6	5.0
R&D expense	0.7	0.7	0.8	0.8	1.0
SG&A expense	4.5	4.2	4.7	4.4	3.8
Operating income	-0.0	1.6	0.8	0.0	-2.7
EBITDA	4.5	6.4	3.5	2.8	-0.4
D&A	4.5	3.0	2.7	2.9	2.8
Pretax income	-0.7	2.8	0.2	-0.6	-3.7
Income tax	0.6	0.7	0.1	0.0	-0.2
Net income	-1.3	2.1	0.1	-0.6	-3.5
Diluted EPS ($)	-1.05	1.71	0.05	-0.53	-3.00
Diluted shares (M)	1,209	1,217	1,207	1,193	1,171

Operating CF$2B

CapEx$0B

Free cash flow$2B

SBC$0B

Buybacks$1B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	1.3	1.0	0.7	1.3
ST investments	0.2	0.2	0.4	0.1
Receivables (net)	4.1	4.0	3.5	3.3
Total current assets	10.6	13.0	9.5	9.2
PP&E (net)	3.3	3.0	2.9	2.9
Goodwill + intangibles	33.0	29.0	26.2	21.9
Total assets	50.0	47.7	41.5	37.2
Accounts payable	1.2	1.4	1.4	1.3
Short-term debt	1.3	1.9	0.0	2.0
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	6.7	7.8	5.8	7.1
Long-term debt	18.0	16.2	14.0	12.5
Total liabilities	28.9	27.2	22.9	22.5
Shareholders' equity	21.1	20.5	18.6	14.7

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	2.1	0.1	(0.6)	(3.5)
D&A	3.0	2.7	2.7	2.8
Stock-based compensation	0.1	0.2	0.1	0.2
Working capital change	(0.9)	(0.7)	(0.3)	(2.5)
Operating cash flow	3.0	2.8	2.3	2.3
Capital expenditures	(0.5)	(0.5)	(0.3)	(0.4)
Investing cash flow	1.5	(0.8)	1.8	(0.4)
Buybacks	0.0	(0.2)	(0.2)	(0.5)
Dividends paid	(0.6)	(0.6)	(0.6)	(0.6)
Debt issuance / (repay)	(3.3)	(1.2)	(3.7)	0.0
Financing cash flow	(3.9)	(2.3)	(4.3)	(1.3)
Free cash flow	2.5	2.3	2.0	1.9

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	-5.8%	10.0%	0.3%	-3.2%	-21.1%	-3%
ROA	-2.2%	4.0%	0.1%	-1.4%	-8.9%	-1.2%
ROIC	-0.1%	3.0%	0.5%	0.0%	-7.5%	-0.2%
Gross margin	31.2%	40.0%	41.7%	38.2%	35.1%	34.8%
Operating margin	-0.2%	9.9%	5.0%	0.1%	-18.6%	-0.6%
Net margin	-7.1%	12.8%	0.4%	-4.3%	-24.6%	-2.8%
EBITDA margin	25.0%	39.6%	22.8%	19.1%	-2.8%	18.4%
FCF margin	14.1%	15.4%	15.1%	13.3%	12.7%	—
VALUATION
P/E	-10.78	5.69	217.20	-22.28	-4.08	-51.8
P/B	0.67	0.56	0.58	0.76	0.98	1.5
P/S	0.76	0.73	0.77	0.96	1.00	1.45
P/FCF	5.43	4.72	5.11	7.23	7.88	11.4
EV/EBITDA	8.06	4.65	8.27	9.70	-69.79	12.6
EV/Revenue	2.02	1.84	1.88	1.86	1.93	2.3
Earnings yield	-9.3%	17.6%	0.5%	-4.5%	-24.5%	-1.89%
FCF yield	18.4%	21.2%	19.6%	13.8%	12.7%	8.74%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.10	1.58	1.67	1.65	1.30	1.58
Quick ratio	0.70	1.05	1.22	0.98	0.74	0.96
Debt / equity	1.14	0.93	0.90	0.77	1.00	0.96
Debt / assets	42.6%	39.0%	38.5%	34.5%	39.5%	38.9%
Net debt / EBITDA	5.01	2.81	4.89	4.69	-33.50	4.69
Interest coverage	-0.04	5.75	1.35	-0.13	-6.78	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.31	0.31	0.32	0.33	0.36	0.42
Receivables turnover	4.67	4.63	5.09	5.36	5.44	4.0
DSO (days)	78	79	72	68	67	91
DPO (days)	36	41	52	55	52	47
Cash conversion cycle	183	177	162	160	169	193
GROWTH (YoY)
Revenue growth	49.7%	-9.1%	-5.1%	-4.5%	-3.0%	—
Net income growth	-89.4%	263.8%	-97.4%	-1259.4%	-454.2%	—
EPS growth	-33.8%	262.2%	-97.3%	-1266.0%	-473.8%	—
FCF growth	157.4%	-0.5%	-7.4%	-15.9%	-6.9%	—
PER SHARE ($)
EPS (diluted, TTM)	-1.05	1.70	0.05	-0.53	-3.05	-0.35
Book value / share	16.94	17.25	17.05	15.62	12.76	12.26
Revenue / share	14.79	13.31	12.85	12.35	12.41	12.67
FCF / share	2.08	2.05	1.94	1.64	1.58	1.61
Cash / share	0.77	1.21	0.99	0.91	1.26	1.30
SHAREHOLDER RETURN & SCORES
Buyback yield	0.0%	0.0%	2.1%	1.8%	3.5%	1.62%
Altman Z-Score	0.68	1.03	0.91	0.94	0.54	1.1
Piotroski F-Score	4	6	7	5	4	7/9
Beneish M-Score	-3.13	-2.63	-2.98	-2.80	-3.23	-2.93

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	1.1	Distress (<1.81)	Distress
Income quality	N/M	Loss-making	OCF ÷ net income not meaningful with negative earnings; OCF itself is the signal
Beneish M-Score	-2.93	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.62
Interest burden	7.59
Operating margin	-0.6%
Asset turnover	0.40×
Financial leverage	2.46×
= ROE	-3%

Growth Quality (live)	Value
Revenue stability	0.59
Earnings stability	0.04
Earnings persistence	0.50
Revenue CAGR 3y	-1.9%
EPS CAGR 3y	—
FCF CAGR 3y	-2.9%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield1.62%

Dividend Yield2.57%

Total Shareholder Return4.63%cash yield

SBC / Revenue1.2%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
ZTS	$32.8B	13.0	64%	28.0%	+1.4%	6/9	-44.4%
ELAN	$11.8B	-57.4	-3%	3.9%	+12.0%	5/9	+14.8%
TEVA	$48.4B	65.4	10%	-13.9%	+4.1%	7/9	+111.4%
ALKS	$6.9B	102.3	4%	0.1%	+10.8%	4/9	+33.8%
LNTH	$6.5B	23.7	22%	19.3%	+2.3%	5/9	—
AMRX	$6.1B	38.6	-396%	7.2%	+9.3%	8/9	—
INDV	$4.0B	11.4	-152%	35.6%	+13.5%	4/9	—
HCM	$2.5B	153.5	47%	5.7%	-11.8%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

13 Analysts

Str Sell (0)Sell (1)Hold (7)Buy (5)Str Buy (0)

Mean Target (qtr)$22.754 targets

Target vs. Price+22.0%last-quarter mean

Next Report2026-11-05street $0.64

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$14.79B	$14.81B / $14.78B	$2.52	$2.56 / $2.47	7
FY2027	$15.04B	$15.39B / $14.88B	$2.69	$2.80 / $2.60	7
FY2028	$15.51B	$15.84B / $15.20B	$2.87	$4.02 / $1.85	3

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$25.50	+36.7%	2
Last Quarter	$22.75	+22.0%	4
Last Year	$19.40	+4.0%	10
All Time	$16.65	-10.7%	17

Rolling mean of published targets vs. last close $18.66. Aggregated from StreetInsider, Benzinga.

Third-Party Composite Rating

C+

DCF

4/5

ROE

1/5

ROA

1/5

Debt/Eq

1/5

P/E

1/5

P/B

4/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

VTRS +87.0% vs S&P 500 +15.9% — spread +71.1pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$17.63	+1.03	+5.81%	Above
SMA 50	$16.96	+1.70	+9.99%	Above
SMA 200	$15.58	+3.08	+19.74%	Above
EMA 9	$17.84	+0.82	+4.57%	Above
EMA 21	$17.57	+1.09	+6.18%	Above
EMA 50	$17.19	+1.46	+8.52%	Above
EMA 200	$15.45	+3.21	+20.74%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +8322 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%94

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago100%+0 pts since

12 Weeks Ago100%+0 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$17.63

Price vs SMA 50$16.96

Price vs SMA 200$15.58

EMA 9/21 Cross17.8/17.6

SMA 50/200Golden

ADX DirectionADX 21

Supertrend$17

Parabolic SAR$17

SMA Slope0.090

RSI69.2

Stochastic K/D74/52

StochRSI K/D60/31

Williams %R-1

CCI218

TSI vs Signal19.1

CMO38.3

ROC6.02%

OBV SignalAccum

Chaikin MF0.110

MFI53

Force Index1M

Elder Ray Bull1.10

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 52

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$18.05 / $18.41 / $18.59	S1 / S2	$17.87 / $17.51
Bollinger (20,2)	$16.84 – $18.43	Squeeze	Off
52-wk range	$9.80 – $18.67	Off 52-wk high	-0.1%
ATR (14)	$0.50 (2.7%)	Historical vol	26.0%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+2.0%Jan60%

-2.9%Feb45%

-2.4%Mar43%

+0.5%Apr35%

-1.1%May50%

-2.2%Jun40%

+0.7%Jul65%

-0.7%Aug50%

-3.5%Sep30%

+1.2%Oct60%

+4.1%Nov65%

+3.8%Dec65%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	VTRS	S&P 500
Weekly volatility (σ, 1y)	4.76%	1.83%
Best / worst week (1y)	+14.2% / -9.5%	—
Max drawdown (5y, monthly)	-56.0%	—
1-week VaR (95%)	-5.9%	—
Beta (5y)	0.88	1.00

VTRS EQUITY WEATHER (LIVE)PARTLY CLOUDY · +23

Trend+45

Momentum+48

Volume+48

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 124 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+22.8+42.6 vs industry

Trend+44.5+65.6 vs industry

Momentum+47.7+72.3 vs industry

Volume+47.5+64.4 vs industry

Reading	VTRS	Drug Manufacturers - Specialty & Generic n=977	Healthcare n=5,272	All US symbols n=70,435
Overall	+22.8	-19.9	-24.0	-20.5
Trend	+44.5	-21.0	-25.6	-21.3
Momentum	+47.7	-24.6	-28.5	-15.8
Volume	+47.5	-16.9	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Scott A. Smith Chief Executive Officer	$15.3M	86% equity+incentive
Corinne Le Goff Chief Commercial Officer	$5.9M	81% equity+incentive
Doretta Mistras Chief Financial Officer	$5.6M	82% equity+incentive
Brian Roman Former Chief Legal Officer	$4.8M	78% equity+incentive
Andrew Enrietti Chief Administrative and Tra	$4.3M	80% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	61
Social	63
Governance	78
Composite ESG	67

Composite ESG Trend

Filed	8-K contents	Items
2026-10-08	Material Agreement; Other Events; Exhibits	1.01,8.01,9.01
2026-08-06	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-07-01	Material Agreement; Financial Obligation; Exhibits	1.01,2.03,9.01
2026-06-18	Material Agreement; Financial Obligation; Exhibits	1.01,2.03,9.01
2026-06-15	Other Events; Exhibits	8.01,9.01
2026-05-15	Shareholder Vote	5.07
2026-05-07	Earnings Release; Other Events; Exhibits	2.02,8.01,9.01
2026-05-04	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-06 to 2026-08-06
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	32 rows · 2010 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-04-15 to 2026-09-30
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-05-05 to 2026-09-08
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Viatris Inc. (VTRS)

Institutions holding — 12 quarters

Viatris Inc. (VTRS)

Monthly Net Insider Flow (000 shares)

Signal Summary

Viatris Inc. (VTRS)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding VTRS — quarterly

Institutional Put/Call — quarterly

Viatris Inc. (VTRS)

Where VTRS Trades in the Dark

Viatris Inc. (VTRS)

3.8 · Employees (SEC filings)

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Balance Sheet — Full

Cash Flow Statement — Full

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Street Price Target — Trajectory

Third-Party Composite Rating

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Family Scores (site weights)

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)

Viatris Inc. (VTRS)